Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: L10 • ACR Convergence 2021
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
joshua solomon¹, Felix Woodhead², Sonye Danoff³, Shana Haynes-Harp⁴, Tanvi Naik⁵, Cathie Spino⁵, Shelley Hurwitz⁶, Rie Maurer⁶, Daniel Chambers⁷, Martin Kolb⁸, Hiliary Goldberg⁶ and Ivan Rosas⁴, ¹National Jewish Health, Denver, CO, ²University of Leicester, Leicester, United Kingdom, ³Johns Hopkins University, Baltimore, MD, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Brigham and Womens Hospital, Boston, MA, ⁷University of Queensland, Brisbane, Australia, ⁸McMaster University, Hamilton, ON, Canada
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…
Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
ELVIRA D'ANDREA¹, Rishi Desai², Mengdong He³, Robert Glynn⁴, Hemin Lee², Michael Weinblatt², Daniel Solomon⁵ and Seoyoung Kim², ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Diego Andrey², Christoph Berger³, Axel Finckh², Pierre Lescuyer², Adrian Ciurea⁴, Tanja Maletic¹, Christos Polysopoulos¹, Myriam Riek¹, Almut Scherer¹, Kim Lauper², Burkhard Moeller⁵, Judith Safford⁶, Sandra Schweizer⁷, Isabell von Loga¹, Nicolas Vuilleumier⁸ and Andrea Rubbert-Roth⁹, ¹SCQM Foundation, Zurich, Switzerland, ²Geneva University Hospital, Geneva, Switzerland, ³University Hospital Basel, Basel, Switzerland, ⁴University Hospital Zurich, Zrich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶RheumaCura Foundation, Zurich, Switzerland, ⁷Swiss League Against Rheumatism, Zurich, Switzerland, ⁸University Hospital of Geneva, Geneva, Switzerland, ⁹Kantonspital St Gallen, St.Gallen, Switzerland
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…
Abstract Number: 166 • 2020 Pediatric Rheumatology Symposium
Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones
Margaret Chang¹, Anais Levescot ², Nathan Nelson-Maney ³, Rachel Blaustein ⁴, Kellen Winden ¹, Allyn Morris ⁴, Spoorthi Balu ⁴, Alexandra Wactor ⁴, Kevin Wei ⁵, Lauren Henderson ⁶, Rachael Clark ⁴, Deepak Rao ⁴, Robert Fuhlbrigge ⁷ and Peter Nigrovic ⁸, ¹Boston Children's Hospital, Boston, ²Boston, ³, ⁴Brigham and Women's Hospital, Boston, ⁵BWH, Boston, ⁶Boston Children's Hospital, Watertown, Massachusetts, ⁷University of Colorado, Aurora, ⁸Boston Children's Hospital, Boston, Massachusetts
Background/Purpose: Resident memory T cells (TRM) are site-specific memory T cells that take up long-term residence in peripheral tissues and aid in pathogen defense. Dysregulated…
Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Evgeniy Nasonov ¹, Saeed Fatenejad ², Elena Korneva ³, Diana Krechikova ⁴, Alexey Maslyansky ⁵, Tatyana Plaksina ⁶, Marina Stanislav ⁷, Rumen Stoilov ⁸, Tamara Tyabut ⁹, Sergey Yakushin ¹⁰, Elena Zonova ¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, Charlotte, North Carolina, ³R-Pharm, Moscow, Russia, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, ⁵SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, ⁶SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁹Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, ¹²Stanford University, Stanford, CA
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
Abstract Number: 1334 • 2019 ACR/ARP Annual Meeting
Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Dalifer Freites Nuñez¹, Leticia León ², Marta Redondo ³, Cristina Vadillo Font ⁴, Pia Lois ⁵, Arkaitz Mucientes Ruiz ⁴, Luis Rodríguez-Rodríguez ⁶, Benjamín Fernández Gutiérrez ⁷, Juan Angel Jover Jover ⁴ and lydia Abasolo Alcazar ⁴, ¹Hospital Clínico San Carlos, MADRID, Spain, ²Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, ³Universidad Camilo José Ceja, Madrid, Madrid, Spain, ⁴HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ⁵Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁶Fundación para la Investigación Biomedica, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid
Background/Purpose: Fatigue is one of the most frequent symptoms in patients with rheumatoid arthritis (RA), affecting more than 80% of them. The experience of fatigue…
Abstract Number: 1361 • 2019 ACR/ARP Annual Meeting
Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Jatin Mistry ¹, Margaret Sibley ², Catherine Smith ³, Malama Sumbwanyambe ² and Patrick Kiely², ¹St George's University of London, London, United Kingdom, ²St George's University Hospitals NHS Trust, London, United Kingdom, ³St Georges University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ACR/EULAR guidelines recommend remission or low DAS28 as the treat to target goal for patients with rheumatoid arthritis (RA). Alternative patient reported outcomes include…
Abstract Number: 1387 • 2019 ACR/ARP Annual Meeting
Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Jeffrey Curtis¹, Daniel Aletaha ², Gerd Burmester ³, Kerri Ford ⁴, Hubert van Hoogstraten ⁵, Henry Leher ⁶, Karthinathan Thangavelu ⁷ and Vivian Bykerk ⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medical University of Vienna, Vienna, Austria, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁷Sanofi Genzyme, Boston, MA, ⁸Hospital for Special Surgery, New York City, NY
Background/Purpose: Guidelines recommend adjusting therapy in patients with RA who fail to reach low disease activity or remission. Partial responders to a TNF inhibitor may…
Abstract Number: 1421 • 2019 ACR/ARP Annual Meeting
Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results
Florencia Pierini¹, Ignacio Gandino ¹, Eliana Botta ², Fernando Brites ², Tomas Meroño ², Osvaldo Luis Cerda ³, Gustavo Citera ⁴, Javier Rosa ⁵, Patricia Sorroche ⁶, Laura Boero ², Maximiliano Martin ², Soledad saez ⁶, Walter Tetzlaff ² and Enrique Soriano ⁷, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Capital Federal, Argentina, ²Universidad de Buenos Aires, Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁵Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁶Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: In patients with Rheumatoid Arthritis (RA), qualitative alterations of low and high density lipoproteins (LDL and HDL, respectively) might partially explain their increased cardiovascular…
Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting
Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study
Marianne Kerski¹, Peter Boersma ², Eric Miller ³, Ashley Brenner ⁴, Genevieve Melton ⁵ and Anna Shmagel ⁶, ¹University of Minnesota Medical School, Minneapolis, MN, ²University of Minnesota School of Public Health, Minneapolis, ³University of Minnesota, Woodbury, MN, ⁴University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, ⁵University of Minnesota Department of Surgery, Minneapolis, MN, ⁶University of Minnesota, Minneapolis, MN
Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
Abstract Number: 1938 • 2019 ACR/ARP Annual Meeting
The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study
Amogh Pathi ¹, Mette Smed ², Lior Pachter ³, Elizabeth Purdom ⁴, Matthew Wright ⁵, Nicholas Jewell ⁴, J. Lee Nelson ⁶, Jørn Olsen ⁷, Merete Lund Hetland ⁸, Vibeke Zoffmann ⁹ and Damini Jawaheer¹⁰, ¹UCSF Benioff Children's Hospital Oakland, Oakland, ²Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Caltech, Pasadena, ⁴University of California Berkeley, Berkeley, ⁵UCSF Benioff Children's Hopsital Oakland, Oakland, ⁶Fred Hutchinson Cancer Research Center, Seattle, ⁷Aarhus University Hospital, Aarhus, Denmark, ⁸DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁹Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, ¹⁰UCSF Benioff Children's Hospital Oakland, Oakland, CA
Background/Purpose: Pregnancy is known to induce a natural improvement of Rheumatoid Arthritis (RA) symptoms in 50-75% of patients as gestation progresses. However, the underlying mechanisms…
Abstract Number: 2091 • 2019 ACR/ARP Annual Meeting
The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients
Mariana Useche ¹, Ramanakumar Agnihotram ¹, Sasha Bernatsky ², Brian Ward ³ and Ines Colmegna³, ¹The Research Institute of the McGill University Health Center, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Center, Montreal, QC, Canada
Background/Purpose: The high dose trivalent inactivated influenza vaccine (HD-TIV) contains four times the antigen dose per strain of the standard-dose inactivated influenza vaccines. HD-TIV is…
Abstract Number: 2258 • 2019 ACR/ARP Annual Meeting
Causes of Influenza Vaccine Hesitancy in Rheumatoid Arthritis and Adults with Juvenile Idiopathic Arthritis
Sandra Pelaez ¹, Vincent Gosselin Boucher ², Valeria Valerio ³, Elizabeth M. Hazel ⁴, Kim Lavoie ⁵, Brian Ward ⁶ and Ines Colmegna⁶, ¹Research Centre of the Sainte-Justine University Hospital, Montreal, Canada, ²Montreal Behavioural Medicine Centre, Centre Intégré Universitaire de santé et services sociaux du Nord-de-l’Ile-de-Montréal (CIUSSS-NIM), Hôpital du Sacré-Cœur de Montréal & Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, Canada, ⁵Montreal Behavioural Medicine Centre, Centre Intégré Universitaire de santé et services sociaux du Nord-de-l’Ile-de-Montréal (CIUSSS-NIM), Hôpital du Sacré-Cœur de Montréal & Department of Psychology, Université du Québec à Montréal, Montreal, Canada, ⁶McGill University Health Center, Montreal, QC, Canada
Background/Purpose: Vaccine hesitancy -the reluctance or refusal to vaccinate despite the availability of vaccines- is one of the threats to global health set by the…

1
2
3
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].